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Background
Although the PDE5 inhibitors were originally targeting
cardiovascular disorders, like congestive heart failure or
angina, the break-through of this class of drugs was their
use in treatment of urological disorders. More than 10
years ago, the clinical introduction of the PDE5i for the
treatment of male erectile dysfunction (ED) was a land-
mark for ED-treatment and is still the gold standard of
care. There is accumulating recent evidence that cGMP ele-
vation within the lower urinary tract – outside penile tis-
sue – could effectively regulate prostate and bladder
function. This might imply a potential new role of PDE5-
I for the treatment of benign prostatic syndrome and
other lower urinary tract disorders.
Results
In preclinical experiments it was shown that PDE5 mRNA
is expressed in rat bladder and prostate tissue and PDE5
protein is localized in bladder smooth muscle cells. On a
functional level, PDE5 inhibition increased cGMP levels
in these tissues significantly. Moreover PDE5 inhibitors
dose-dependently relaxed rat bladder, prostate and ure-
thra strips. In vivo, PDE5-I dose-dependently reduced non
voiding contractions in rats with partial bladder outlet
obstruction (BOO) mimicking benign prostatic obstruc-
tion in the patient. Non-voiding contractions – a correlate
for irritative symptoms – were significantly reduced in
BOO-rats after acute and chronic treatment with PDE5
inhibitors. In addition the voiding frequency could be sig-
nificantly decreased with PDE5-I treatment in anaesthe-
tized and conscious rats with detrusor over-activity.
Finally in conscious dogs voiding frequency was also
reduced after PDE5-I treatment. Phase II clinical trials
have already confirmed these pre-clinical findings and
have shown that in symptomatic BPH patients, sildenafil,
tadalafil and vardenafil reduced lower urinary tract symp-
toms. After chronic daily treatment with these PDE5
inhibitors for 8 to 12 week the IPPS (international pros-
tatic symptom score) was significantly reduced.
Conclusion
Preclinical and clinical findings show that PDE5 inhibi-
tors could be an effective treatment option for LUTS sec-
ondary to BPH patients in the future. In addition these
compounds might have up-side potential for the treat-
ment of overactive bladder.
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